scholarly journals Biosynthesis of inositol trisphosphate receptors: selective association with the molecular chaperone calnexin

1999 ◽  
Vol 342 (1) ◽  
pp. 153-161 ◽  
Author(s):  
Suresh K. JOSEPH ◽  
Darren BOEHNING ◽  
Shaila BOKKALA ◽  
Richard WATKINS ◽  
Johan WIDJAJA

A prominent labelled polypeptide having the same mobility as type-I inositol trisphosphate receptor (IP3R) was immunoprecipitated from WB-cell lysates by antibodies to calnexin, an ER integral membrane chaperone. The identity of this polypeptide was confirmed by re-immunoprecipitation of the radioactive polypeptides released from calnexin-antibody immunoprecipitates with type-I IP3R antibody. The interaction of calnexin with newly synthesized type-I IP3R was transient and inhibited by treatment of the cells with dithiothreitol or the glucosidase inhibitor N-methyldeoxynojirimicin. In similar experiments, there was no evidence for the binding of type-I IP3R to calreticulin, an ER luminal chaperone. Calnexin (but not calreticulin) associated with newly synthesized FLAG (DYKDDDDK epitope)-tagged type-III IP3R expressed in COS-7 cells. In order to further define the mechanism of interaction of nascent IP3R with chaperones, we have utilized an in vitro rabbit reticulocyte translation assay programmed with RNA templates encoding the six putative transmembrane (TM) domains of IP3Rs. In accordance with the known preference of calnexin for monoglucosylated oligosaccharide chains, calnexin antibody preferentially immunoprecipitated a proportion of glycosylated type-I translation product. Addition of glucosidase inhibitors prevented the association of calnexin with in vitro translated type-I TM construct. Using truncated RNA templates we found that calnexin did not associate with the first four TM domains but retained affinity for the construct encoding TM domains 5 and 6, which contains the glycosylation sites. We propose that calnexin is a key chaperone involved in the folding, assembly and oligomerization of newly synthesized IP3 receptors in the ER.

2013 ◽  
Vol 104 (2) ◽  
pp. 121a
Author(s):  
Spyros Zissimopoulos ◽  
Jason Marsh ◽  
F. Anthony Lai

Planta Medica ◽  
2021 ◽  
Author(s):  
Neil Miller ◽  
Elizabeth Joubert

AbstractPostprandial hyperglycemia is treated with the oral antidiabetic drug acarbose, an intestinal α-glucosidase inhibitor. Side effects of acarbose motivated a growing number of screening studies to identify novel α-glucosidase inhibitors derived from plant extracts and other natural sources. As “gold standard”, acarbose is frequently included as the reference standard to assess the potency of these candidate α-glucosidase inhibitors, with many outperforming acarbose by several orders of magnitude. The results are subsequently used to identify suitable compounds/products with strong potential for in vivo efficacy. However, most α-glucosidase inhibitor screening studies use enzyme preparations obtained from nonmammalian sources (typically Saccharomyces cerevisiae), despite strong evidence that inhibition data obtained using nonmammalian α-glucosidase may hold limited value in terms of identifying α-glucosidase inhibitors with actual in vivo hypoglycemic potential. The aim was to critically discuss the screening of novel α-glucosidase inhibitors from plant sources, emphasizing inconsistencies and pitfalls, specifically where acarbose was included as the reference standard. An assessment of the available literature emphasized the cruciality of stating the biological source of α-glucosidase in such screening studies to allow for unambiguous and rational interpretation of the data. The review also highlights the lack of a universally adopted screening assay for novel α-glucosidase inhibitors and the commercial availability of a standardized preparation of mammalian α-glucosidase.


1999 ◽  
Vol 341 (2) ◽  
pp. 401 ◽  
Author(s):  
Roland B. GREGORY ◽  
Robert A. WILCOX ◽  
Leise A. BERVEN ◽  
Nicole C.R. VAN STRATEN ◽  
Gijs A. VAN DER MAREL ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document